Concepedia

Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial

A. Michael Lincoff, Jean‐Claude Tardif, Bruce Neal, Stephen J. Nicholls, Lars Rydén, Gregory G. Schwartz, Klas Malmberg, John B. Buse, Robert R. Henry, Hans Wedel,

American Heart Journal · 2013 · 40 citations · 33 references

DOI

Concepts

References

33

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 20.1K citations

, , +13

Effects of Intensive Glucose Lowering in Type 2 Diabetes

New England Journal of Medicine · 2008 · 7.9K citations · Full text

, , +14

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine · 2008 · 7.4K citations · Full text

, , +16

Universal Definition of Myocardial Infarction

Kristian Thygesen, Joseph S. Alpert, Harvey D. White · Circulation · 2007 · 4.2K citations

, , +12

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

, , +15